All News Caribou Biosciences, Inc.

Equities

CRBU

US1420381089

Market Closed - Nasdaq Other stock markets 01:30:00 19/06/2024 am IST			5-day change	1st Jan Change
1.64 ^USD	-6.29%		-16.75%	-71.38%

04/06	US Equities Markets Close Mixed Monday as US Manufacturing Contracts	MT
04/06	HC Wainwright Adjusts Price Target on Caribou Biosciences to $9 From $24, Maintains Buy Rating	MT

All News

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pomerantz Law Firm Investigates Claims On Behalf of Investors of Caribou Biosciences, Inc. - CRBU	15/06	PR
US Equities Markets Close Mixed Monday as US Manufacturing Contracts	04/06	MT
HC Wainwright Adjusts Price Target on Caribou Biosciences to $9 From $24, Maintains Buy Rating	04/06	MT
Sector Update: Health Care Stocks Gain Late Afternoon	04/06	MT
Sector Update: Health Care	04/06	MT
Top Midday Decliners	03/06	MT
Caribou Biosciences Shares Fall After Evercore ISI Downgrade on Post Clinical Trial Results	03/06	MT
Caribou Biosciences : CB-010 ANTLER Update ASCO 2024	03/06	PU
Caribou Biosciences : CB-012 AMpLify Study Trial Design ASCO 2024	03/06	PU
Top Premarket Decliners	03/06	MT
Evercore ISI Downgrades Caribou Biosciences to In-Line Rating With $3 Price Target	03/06	MT
Caribou Biosciences : Corporate Presentation May 2024	03/06	PU
Caribou Biosciences : KOL discussion of CB-010 ANTLER Phase 1 final trial data at ASCO	03/06	PU
Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	03/06	AQ
Caribou Biosciences, Inc. Presents Encouraging Clinical Data from CB-010 Antler Phase 1 Trial in Second-Line Lbcl Patients At the 2024 American Society of Clinical Oncology Annual Meeting	03/06	CI
Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences	31/05	AQ
Caribou Biosciences : Cas12a chRDNA in vivo editing ASGCT 2024	10/05	PU
Truist Adjusts Price Target on Caribou Biosciences to $19 From $21, Maintains Buy Rating	09/05	MT
Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update	08/05	AQ
Caribou Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

All News Caribou Biosciences, Inc.

Equities

CRBU

US1420381089

All News

Filters